Why have we failed to achieve neuroprotection in Parkinson's disease?

Annals of Neurology

Volumn 64, Issue SUPPL. 2, 2008, Pages

  Olanow, C Warren ^a   Kieburtz, Karl ^b   Schapira, Anthony H V ^c  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF ROCHESTER MEDICAL CENTER   (United States)

^c ROYAL FREE AND UNIVERSITY COLLEGE MEDICAL SCHOOL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIPARKINSON AGENT; CEP 1347; DESMETHYLSELEGILINE; DOPAMINE; DOPAMINE RECEPTOR STIMULATING AGENT; GLIAL CELL LINE DERIVED NEUROTROPHIC FACTOR; IMMUNOPHILIN; LEVODOPA; PLACEBO; PRAMIPEXOLE; RASAGILINE; RILUZOLE; ROPINIROLE; SELEGILINE; TCH 346; TOCOPHEROL; UBIDECARENONE; UNCLASSIFIED DRUG;

CELL DEATH; CLINICAL FEATURE; CLINICAL TRIAL; DISEASE COURSE; DOSE RESPONSE; DRUG ACTIVITY; DRUG EFFECT; DRUG MECHANISM; DRUG METABOLISM; HUMAN; NEUROPROTECTION; NONHUMAN; PARKINSON DISEASE; PATHOGENESIS; PRIORITY JOURNAL; REVIEW; TREATMENT OUTCOME;

ANIMALS; CLINICAL TRIALS AS TOPIC; DISEASE MODELS, ANIMAL; HUMANS; MONOAMINE OXIDASE INHIBITORS; NEUROPROTECTIVE AGENTS; PARKINSON DISEASE;

EID: 58349122472     PISSN: 03645134     EISSN: 15318249     Source Type: Journal    
DOI: 10.1002/ana.21461     Document Type: Review

References (55)

1. Olanow CW, Watts RL, Koller WC. An algorithm (decision tree) for the management of Parkinson's disease (2001): treatment guidelines. Neurology 2001;56(suppl 5):1-88.
2. Chaudhuri KR, Martinez-Martin P, Schapira AH, et al. International multicenter pilot study of the first comprehensive self-completed nonmotor symptoms questionnaire for Parkinson's disease: the NMSQuest study. Mov Disord 2006;21:916-923.
3. Hely MA, Morris JG, Reid WG, Trafficante R. Sydney Multicenter Study of Parkinson's disease: non-L-dopa-responsive problems dominate at 15 years. Mov Disord 2005;20:190-199.
4. Olanow CW, Schapira A, Agid Y. Causes of cell death and prospects for neuroprotection in Parkinson's disease. Ann Neurol 2002;53(suppl 3):1-170.
5. Olanow CW. Pathogenesis of cell death in Parkinson's disease - 2007. Mov Disord 2007;22:S335-S342.
6. Dawson TM, Dawson VL. Molecular pathways of neurodegeneration in Parkinson's disease. Science 2003;302:819-822.
7. Parkinson Study Group. Effects of tocopherol and deprenyl on the progression of disability in early Parkinson's disease. N Engl J Med 1993;328:176-183.
8. Olanow CW, Schapira AHV, Lewitt PA, et al. TCH346 as a neuroprotective drug in Parkinson's disease: a double-blind, randomised, controlled trial. Lancet Neurol 2006;5:1013-1020.
9. Rascol O, Olanow W, Brooks D, et al. A 2-year multicenter, placebo-controlled, double-blind, parallel-group study of the effect of riluzole on Parkinson's disease progression. Mov Disord 2002;17(suppl 5):39.
10. Parkinson Study Group PRECEPT Investigators. Mixed lineage kinase inhibitor CEP-1347 fails to delay disability in early Parkinson disease. Neurology 2007;69:1480-1490.
11. Lang AE, Gill S, Patel NK, et al. Randomized controlled trial of intraputamenal glial cell line-derived neurotrophic factor infusion in Parkinson disease. Ann Neurol 2006;59:459-466.
12. Gold BG, Nutt JG. Neuroimmunophilin ligands in the treatment of Parkinson's disease. Curr Opin Pharmacol 2002;2:82-86.
13. Olanow CW, Hauser RA, Gauger L, et al. The effect of deprenyl and levodopa on the progression of Parkinson's disease. Ann Neurol 1995;38:771-777.
14. Shults CW, Oakes D, Kieburtz K, et al. Effects of coenzyme Q10 in early Parkinson disease: evidence of slowing of the functional decline. Arch Neurol 2002;59:1541-1550.
15. Parkinson Study Group. Dopamine transporter brain imaging to assess the effects of pramipexole vs levodopa on Parkinson disease progression. JAMA 2002;287:1653-1661.
16. Whone A, Watts R, Stoessl J, et al. Slower progression of Parkinson's disease with ropinirole versus levodopa: the REALPET Study. Ann Neurol 2003;54:93-101.
17. Fahn S, Oakes D, Shoulson I, et al; Parkinson Study Group. Does levodopa slow or hasten the rate of progression of Parkinson disease? The results of the ELLDOPA study. N Engl J Med 2004;351:2498-2508.
18. Parkinson Study Group. A controlled, randomized, delayed-start study of rasagiline in early Parkinson's disease. Arch Neurol 2004;61:561-566.
19. Mytilineou C, Radcliffe PM, Olanow CW. L-(-)-desmethylselegiline, a metabolite of selegiline [L-(-)-deprenyl], protects mesencephalic dopamine neurons from excitotoxicity in vitro. J Neurochem 1997;68:434-436.
20. Carlile GW, Chalmers-Redman RME, Tatton NA, et al. Reduced apoptosis after nerve growth factor and serum withdrawal: conversion of tetrameric glyceraldehydes-3-phosphate dehydrogenase to a dimer. Mol Pharmacol 2000;57:2-12.
21. Olanow CW, Calne D. Does selegiline monotherapy in Parkinson's disease act by symptomatic or protective mechanisms? Neurology 1991;42(suppl 4):13-26.
22. Shoulson I, Oakes D, Fahn S, et al. Impact of sustained deprenyl (selegiline) in levodopa-treated Parkinson's disease: a randomized placebo-controlled extension of the deprenyl and tocopherol antioxidative therapy of parkinsonism trial. Ann Neurol 2002;51:604-612.
23. Pålhagen S, Heinonen E, Hägglund J, et al; Swedish Parkinson Study Group. Selegiline slows the progression of the symptoms of Parkinson disease. Neurology 2006;66:1200-1206.
24. Mandel S, Weinreb O, Amit T, Youdim MB. Mechanism of neuroprotective action of the anti-Parkinson drug rasagiline and its derivatives. Brain Res Brain Res Rev 2005;48:379-387.
25. Schapira AH, Cooper JM, Dexter D, et al. Mitochondrial complex I deficiency in Parkinson's disease. Lancet 1989;1:1269.
26. Olanow CW, Jenner P, Brooks D. Dopamine agonists and neuroprotection in Parkinson's disease. Ann Neurol 1998;44:167-174.
27. Schapira AH. Dopamine agonists and neuroprotection in Parkinson's disease. Eur J Neurol 2002;9(suppl 3):7-14.
28. Nair VD, Olanow CW, Sealfon SC. Activation of phosphoinositide 3-kinase by D2 receptor prevents apoptosis in dopaminergic cell lines. Biochem J 2003;373:25-32.
29. Nair VD, Olanow CW. Differential modulation of Akt/ glycogen synthase kinase-3beta pathway regulates apoptotic and cytoprotective signaling responses. J Biol Chem 2008;283:15469-15478.
30. Gu M, Iravani MM, Cooper JM, et al. Pramipexole protects against apoptotic cell death by non-dopaminergic mechanisms. J Neurochem 2004;91:1075-1081.
31. Iravani MM, Haddon CO, Cooper JM, et al. Pramipexole protects against MPTP toxicity in non-human primates. J Neurochem 2006;96:1315-1321.
32. Ahlskog JE. Slowing Parkinson's disease progression: recent dopamine agonist trials. Neurology 2003;60:381-389.
33. Jennings DL, Tabamo R, Seibyl JP, Marek K. INSPECT: investigating the effect of short-term treatment with pramipexole or levodopa on 123Iβ-CIT-SPECT imaging. Mov Disord 2007;22:113.
34. Kieburtz K, Olanow CW. Translational experimental therapeutics. The translation of laboratory-based discovery into diseaserelated therapy. Mt Sinai J Med 2007;74:7-14.
35. Zimprich A, Biskup S, Leitner P, et al. Mutations in LRRK2 cause autosomal-dominant parkinsonism with pleomorphic pathology. Neuron 2004;44:601-607.
36. Charbonnier F. Exercise-induced neuroprotection in SMA model mice: a means for determining new therapeutic strategies. Mol Neurobiol 2007;35:217-223.
37. Petzinger GM, Walsh JP, Akopian G, et al. Effects of treadmill exercise on dopaminergic transmission in the 1-methyl-4-phenyl-1, 2,3,6- tetrahydropyridine-lesionedmouse model of basal ganglia injury. J Neurosci 2007;27: 5291-5300.
38. U.S. Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research. Guidance for industry: estimating the maximum safe starting dose in initial clinical trials for therapeutics in adult healthy volunteers. July 7, 2005;J: I'GUIDANCE 5541fnlclnl-.doc1 1-27.
39. McNaught KS, Olanow CW, Halliwell B, et al. Failure of the ubiquitin-proteasome system in Parkinson's disease. Nat Rev Neurosci 2001;2:589-594.
40. Olanow CW, McNaught K. The ubiquitin-proteasome system in Parkinson's disease. Mov Disord 2006;21:1806-1823.
41. Martinez-Vicente M, Cuervo AM. Autophagy and neurodegeneration: when the cleaning crew goes on strike. Lancet Neurol 2007;6:352-361.
42. Schapira AH. Mitochondria in the aetiology and pathogenesis of Parkinson's disease. Lancet Neurol 2008;7:97-109.
43. Savitz SI, Fisher M. Future of neuroprotection for acute stroke: in the aftermath of the SAINT trials. Ann Neurol 207;61:396-402.
44. Ravina BM, Fagan SC, Hart RG, et al. Neuroprotective agents for clinical trials in Parkinson's disease. A systematic assessment. Neurology 2003;60:1234-1240.
45. NINDS NET-PD Investigators. A randomized, double-blind, futility clinical trial of creatine and minocycline in early Parkinson disease. Neurology 2006;66:664-671.
46. The NINDS NET-PD Investigators. A randomized clinical trial of Coenzyme Q10 and GPI-1485 in early Parkinson's disease. Neurology 2007;68:20-28.
47. Kappos L, Freedman MS, Polman CH, et al. Effect of early versus delayed interferon beta-1b treatment on disability after a first clinical event suggestive of multiple sclerosis: a 3-year follow-up analysis of the BENEFIT study. Lancet 2007;370:389-397.
48. Leber P. Slowing the progression of Alzheimer disease: methodologic issues. Alzheimer Dis Assoc Disord 1997;11(suppl 5):S10-S21; discussion S37-S39.
49. Clarke CE. Are delayed-start design trials to show neuroprotection in Parkinson's disease fundamentally flawed? Mov Disord 2008;23:784-789.
50. Schapira AH, Obeso J. Timing of treatment initiation in Parkinson's disease: a need for reappraisal? Ann Neurol 2006;59:559-562.
51. Olanow CW, Hauser R, Jankovic J, et al. A randomized, double-blind, placebo-controlled, delayed start study to assess rasagiline as a disease modifying therapy in Parkinson's disease (The Adagio Study): rationale, design, and baseline characteristics. Mov Disord (in press).
52. Parkinson Study Group. A randomized placebo-controlled trial of Rasagiline in levodopa-treated patients with Parkinson disease and motor fluctuations. The PRESTO study. Arch Neurol 2005;62:241-248.
53. Parkinson Study Group. Entacapone improves motor fluctuations in levodopa-treated Parkinson's disease patients. Ann Neurol 1997;42:747-755.
54. Langston JW. The Parkinson's complex: parkinsonism is just the tip of the iceberg. Ann Neurol 2006;59:591-596.
55. Stern MB. The preclinical detection of Parkinson's disease: ready for prime time? Ann Neurol 2004;56:169-171.